Mr. Speaker, several years ago, the partnership with CanSinoBIO resulted in the distribution of a vaccine for the Ebola virus in West Africa, a collaboration that had a significant and positive impact around the world.
That is why we considered CanSinoBIO among all the other vaccine candidates we studied. We followed up and had negotiations and discussions with many companies that produce different vaccines. As a result, we now have the best portfolio of potential vaccines in the world, and more potential doses per Canadian than any other country in the world.